Navigation Links
Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients

Hematide in hemodialysis patients with stable baseline Hgb levels between 10 and 12.5 g/dL on previous Epoetin Alfa therapy. The endpoints were Hgb and reticulocyte levels, Hematide dose adjustments and red blood cell transfusions. In addition, adverse and serious adverse events were monitored.

Pharmacodynamic data were presented on the 90 patients who had completed six months of treatment. Mean reticulocyte increases were observed after every Hematide injection. The mean Hgb level, which was 11.5 g/dL at baseline, was maintained within +/- 1 g/dL at the end of six months of treatment. In the 165 patients who received drug in this study, Hematide was generally well tolerated with an adverse event profile consistent with the hemodialysis patient population.

About Hematide

Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program, the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, regulatory requirements and approvals, research and deve
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015 ... is essential to meeting challenges in clinical development, market ... face tighter regulations, the Medical Affairs function is expected ... by mature markets. According to research ... study participants have a group dedicated to Medical Affairs. ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... 27, 2015  Victoria Vein & Surgery Clinic is the ... Duality laser in Victoria, Texas . The ... as advanced laser treatments for a variety of medical and ... to provide more services for their patients. Since adding laser ... Victoria residents get rid of their unwanted ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... RENO, Nev., April 12, 2011 Visual Healthcare Corp. (the ... on a Chinese based adaptation of the information technology grid ... This project has been launched in response to ... Research Organization experts responding to Chinese government resolve to create ...
... Md., April 12, 2011 Neuralstem, Inc. (NYSE Amex: ... Ph.D., Principal Investigator of the Phase I safety trial ... amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease), and ... first nine patients. Dr. Feldman reported yesterday at the ...
Cached Medicine Technology:Visual Healthcare to Support Chinese Clinical Trials 2Visual Healthcare to Support Chinese Clinical Trials 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... 2015 Servpro of Paso Robles ... released a report about the link between mold and ... and according to recent medical research, may even cause ... the Environmental Protection Agency, people with sensitivity to mold ... mold may trigger asthma attacks for asthma sufferers. The ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with the ... for the 2015 and 2016 season. As the Storm’s exclusive ... athletic trainer for the team throughout each season. Tonight, the ... Cleveland Gladiators at Amalie Arena; the game starts at 7:30pm. ... as it gives us the opportunity, to provide health and ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Healthpointe is ... G. Katz, M.D., is now treating knee and hip ... Anaheim , Long Beach, and La Mirada. Dr. ... acute knee and hip joint disorders as well as ... is passionate in returning his patients back to their ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... , ... ... ... ...
... Farmers, markets are not created equal. Some sell only ... of vendors. And each market,s unique personality attracts some people ... based on what they offer, farmers, markets self-select people who ... stores isn,t one of them. "Not one of the ...
... ... ... ... ...
... ... ... ... ...
... ... ... , , ... ...
... ... ... , ... , , , ...
Cached Medicine News:Health News:Health Groups Ask Supreme Court to Authorize Financial Penalties on Tobacco Companies for Decades of Wrongdoing 2Health News:Health Groups Ask Supreme Court to Authorize Financial Penalties on Tobacco Companies for Decades of Wrongdoing 3Health News:Farmers' markets offer different strokes for different folks 2Health News:Farmers' markets offer different strokes for different folks 3Health News:Census Bureau News -- 2007 Economic Census: Health Care and Social Assistance Geographic Area Series (NAICS 62) 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations 2Health News:With Record Registration of 13,000 Runners to Date, the 2010 Dick's Sporting Goods Pittsburgh Marathon Announces a Cap of 16,000 2Health News:With Record Registration of 13,000 Runners to Date, the 2010 Dick's Sporting Goods Pittsburgh Marathon Announces a Cap of 16,000 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: